SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Monsanto Co/New – ‘10-Q’ for 5/31/13 – ‘EX-3.1’

On:  Thursday, 6/27/13, at 3:44pm ET   ·   For:  5/31/13   ·   Accession #:  1110783-13-110   ·   File #:  1-16167

Previous ‘10-Q’:  ‘10-Q’ on 4/4/13 for 2/28/13   ·   Next:  ‘10-Q’ on 1/8/14 for 11/30/13   ·   Latest:  ‘10-Q’ on 4/5/18 for 2/28/18

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 6/27/13  Monsanto Co/New                   10-Q        5/31/13   94:13M

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    833K 
 3: EX-3.1      Articles of Incorporation/Organization or Bylaws    HTML     57K 
 2: EX-12       Statement re: Computation of Ratios                 HTML     50K 
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     33K 
 5: EX-31.2     Certification -- §302 - SOA'02                      HTML     33K 
 6: EX-32       Certification -- §906 - SOA'02                      HTML     28K 
91: R1          Document and Entity Information                     HTML     51K 
60: R2          Statements of Consolidated Operations (Unaudited)   HTML    184K 
56: R3          Statements of Consolidated Comprehensive Income     HTML    105K 
                (Loss) (Unaudited)                                               
17: R4          Statements of Consolidated Comprehensive Income     HTML     46K 
                (Loss) (Parenthetical)                                           
58: R5          Statements of Consolidated Financial Position       HTML    184K 
                (Unaudited)                                                      
40: R6          Statements of Consolidated Financial Position       HTML     46K 
                (Parenthetical) (Unaudited)                                      
80: R7          Statements of Consolidated Cash Flows (Unaudited)   HTML    186K 
41: R8          Statements of Consolidated Shareholders Equity      HTML     86K 
                (Unaudited)                                                      
44: R9          Statements of Consolidated Shareholders Equity      HTML     29K 
                (Parenthetical) (Unaudited)                                      
18: R10         Background and Basis of Presentation                HTML     39K 
42: R11         New Accounting Standards                            HTML     40K 
79: R12         Business Combinations                               HTML     53K 
73: R13         Customer Financing Programs                         HTML     69K 
57: R14         Variable Interest Entities                          HTML     58K 
87: R15         Restructuring                                       HTML     52K 
77: R16         Receivables                                         HTML     46K 
15: R17         Inventory                                           HTML     41K 
22: R18         Goodwill and Other Intangible Assets                HTML     96K 
86: R19         Investments and Equity Affiliates                   HTML     41K 
90: R20         Deferred Revenue                                    HTML     40K 
92: R21         Income Taxes                                        HTML     32K 
89: R22         Debt and Other Credit Arrangements                  HTML     34K 
65: R23         Fair Value Measurements                             HTML    199K 
19: R24         Financial Instruments                               HTML    240K 
38: R25         Postretirement Benefits - Pensions, Health Care     HTML    123K 
                and Other                                                        
27: R26         Stock Based Compensation Plans Stock Based          HTML     73K 
                Compensation Plans                                               
26: R27         Accumulated Other Comprehensive Loss                HTML     42K 
46: R28         Earnings Per Share                                  HTML     45K 
64: R29         Supplemental Cash Flow Information                  HTML     35K 
75: R30         Commitments and Contingencies                       HTML     42K 
32: R31         Segment and Geographic Data                         HTML    147K 
47: R32         Subsequent Events                                   HTML     31K 
83: R33         Business Combinations (Tables)                      HTML     36K 
29: R34         Customer Financing Programs (Tables)                HTML     60K 
71: R35         Variable Interest Entities (Tables)                 HTML     54K 
72: R36         Restructuring (Tables)                              HTML     47K 
49: R37         Receivables (Tables)                                HTML     37K 
25: R38         Inventory (Tables)                                  HTML     39K 
70: R39         Goodwill and Other Intangible Assets (Tables)       HTML     93K 
30: R40         Fair Value Measurements (Tables)                    HTML    180K 
45: R41         Financial Instruments (Tables)                      HTML    222K 
76: R42         Postretirement Benefits - Pensions, Health Care     HTML    114K 
                and Other (Tables)                                               
36: R43         Stock Based Compensation Plans (Tables)             HTML     71K 
66: R44         Accumulated Other Comprehensive Loss (Tables)       HTML     38K 
55: R45         Earnings Per Share (Tables)                         HTML     44K 
28: R46         Supplemental Cash Flow Information Supplemental     HTML     33K 
                Cash Flow Information (Tables)                                   
82: R47         Segment and Geographic Data (Tables)                HTML    143K 
23: R48         Background and Basis of Presentation Background     HTML     27K 
                and Basis of Presentation (Details)                              
31: R49         Business Combinations (Details)                     HTML     72K 
54: R50         Customer Financing Programs (Details)               HTML     52K 
61: R51         VARIABLE INTEREST ENTITIES Narrative (Details)      HTML     31K 
81: R52         VARIABLE INTEREST ENTITIES VARIABLE INTEREST        HTML     51K 
                ENTITIES Schedules (Details)                                     
16: R53         VARIABLE INTEREST ENTITIES Business Acquisitions    HTML     28K 
                (Details)                                                        
68: R54         Restructuring (Details)                             HTML     40K 
51: R55         Receivables (Details)                               HTML     48K 
21: R56         Inventory (Details)                                 HTML     42K 
24: R57         GOODWILL AND OTHER INTANGIBLE ASSETS Schedule of    HTML     41K 
                net carrying amount of goodwill (Details)                        
59: R58         GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND   HTML     58K 
                OTHER INTANGIBLE ASSETS Information of other                     
                intangible assets (Details)                                      
85: R59         GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND   HTML     37K 
                OTHER INTANGIBLE ASSETS Schedule of estimated                    
                amortization expense (Details)                                   
94: R60         INVESTMENTS AND EQUITY AFFILIATES Investments       HTML     51K 
                (Details)                                                        
93: R61         INVESTMENTS AND EQUITY AFFILIATES Investments AND   HTML     40K 
                EQUITY AFFILIATES Equity Affiliates (Details)                    
74: R62         Deferred Revenue (Details)                          HTML     60K 
35: R63         Income Taxes (Details)                              HTML     29K 
33: R64         Debt and Other Credit Arrangements (Details)        HTML     43K 
69: R65         FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS     HTML     90K 
                Fair Value Hierarchy Levels (Details)                            
84: R66         FAIR VALUE MEASUREMENTS Summary of the Change in    HTML     33K 
                Level 3 Liability (Details)                                      
20: R67         FINANCIAL INSTRUMENTS Narrative (Details)           HTML     40K 
88: R68         FINANCIAL INSTRUMENTS FINANCIAL INSTRUMENTS         HTML     34K 
                Notional Amounts of Derivative Instruments                       
                Outstanding (Details)                                            
37: R69         FINANCIAL INSTRUMENTS FINANCIAL INSTRUMENTS Fair    HTML     55K 
                Value of Derivatives Outstanding (Details)                       
50: R70         FINANCIAL INSTRUMENTS FINANCIAL INSTRUMENTS Gain    HTML     88K 
                (Loss) from Derivatives (Details)                                
48: R71         Postretirement Benefits - Pensions, Health Care     HTML     77K 
                and Other (Details)                                              
34: R72         STOCK BASED COMPENSATION PLANS Schedule of          HTML     41K 
                Stock-based Compensation Expense (Details)                       
43: R73         STOCK BASED COMPENSATION PLANS STOCK BASED          HTML     43K 
                COMPENSATION PLANS Restricted Stock (Details)                    
78: R74         Accumulated Other Comprehensive Loss (Details)      HTML     54K 
63: R75         Earnings Per Share (Details)                        HTML     43K 
13: R76         Supplemental Cash Flow Information (Details)        HTML     32K 
67: R77         Commitments and Contingencies (Details)             HTML     36K 
14: R78         Segment and Geographic Data (Details)               HTML     85K 
62: R79         SUBSEQUENT EVENTS Subsequent Events (Details)       HTML     33K 
53: XML         IDEA XML File -- Filing Summary                      XML    141K 
52: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS   2.19M 
 7: EX-101.INS  XBRL Instance -- mon-20130531                        XML   3.67M 
 9: EX-101.CAL  XBRL Calculations -- mon-20130531_cal                XML    277K 
10: EX-101.DEF  XBRL Definitions -- mon-20130531_def                 XML    624K 
11: EX-101.LAB  XBRL Labels -- mon-20130531_lab                      XML   1.92M 
12: EX-101.PRE  XBRL Presentations -- mon-20130531_pre               XML    993K 
 8: EX-101.SCH  XBRL Schema -- mon-20130531                          XSD    223K 
39: ZIP         XBRL Zipped Folder -- 0001110783-13-000110-xbrl      Zip    296K 


‘EX-3.1’   —   Articles of Incorporation/Organization or Bylaws


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  MON-EX3.1_2013.05.31-Q3  


EXHIBIT 3.1

 
 
 
 
State of Delaware
 
 
 
 
Secretary of State
 
 
 
 
Division of Corporations
 
 
 
 
Delivered 06:17 PM 04/17/2013
 
 
 
 
FILED 06:02 PM 04/17/2013
 
 
 
 
SRV 130450387 - 3174788 FILE

RESTATED CERTIFICATE OF INCORPORATION
OF
MONSANTO COMPANY

Monsanto Company, a corporation organized and existing under the laws of the State of Delaware, does hereby certify:
1.    The name of the corporation is Monsanto Company. Monsanto Company was originally incorporated under the name “Monsanto Ag Company”, and the original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on February 9, 2000.
2.    This Restated Certificate of Incorporation only restates and integrates and does not further amend the provisions of Monsanto Company's Certificate of Incorporation as theretofore amended or supplemented and there is no discrepancy between the provisions of the Certificate of Incorporation as theretofore amended and supplemented and the provisions of this Restated Certificate. This Restated Certificate of Incorporation (the Certificate of Incorporation) was duly adopted in accordance with the provisions of Section 245 of the General Corporation Law of the State of Delaware.
3.    The text of the Certificate of Incorporation is hereby restated and integrated to read in its entirety as follows:
ARTICLE I
The name of the corporation (which is hereinafter referred to as the “Corporation”) is: Monsanto Company

ARTICLE II
The address of the Corporation's registered office in the State of Delaware is 2711 Centerville Road, Suite 400, Wilmington, Delaware 19808, County of New Castle. The name of the Corporation's registered agent at such address is Corporation Service Company.
ARTICLE III
The purpose of the Corporation shall be to engage in any lawful act or activity for which corporations may be organized and incorporated under the General Corporation Law of the State of Delaware.

1



ARTICLE IV
Section 1.     The Corporation shall be authorized to issue 1,520,000,000 shares of capital stock, of which 1,500,000,000 shares shall be shares of Common Stock, $0.01 par value (“Common Stock”), and 20,000,000 shares shall be shares of Preferred Stock, $0.01 par value (“Preferred Stock”).
Section 2.     Shares of Preferred Stock may be issued from time to time in one or more series. The Board of Directors of the Corporation (the “Board”) is hereby authorized to fix by resolution or resolutions the voting powers, if any, designations, powers, preferences and the relative, participating, optional or other special rights, if any, and the qualifications, limitations or restrictions thereof, of any unissued series of Preferred Stock; and to fix the number of shares constituting such series, and to increase or decrease the number of shares of any such series (but not below the number of shares thereof then outstanding). The powers, preferences and relative, participating, optional and other special rights of each series of Preferred Stock, and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding.
Section 3.     Except as otherwise provided by law or by this Certificate of Incorporation (including any certificate filed with the Secretary of State of the State of Delaware establishing the terms of a series of Preferred Stock in accordance with Section 2 of this Article IV), the Common Stock shall have the exclusive right to vote for the election of directors and for all other purposes. Each share of Common Stock shall entitle the holder thereof to one vote on all matters on which stockholders are entitled generally to vote, and the holders of Common Stock shall vote together as a single class.
ARTICLE V
Section 1.     In anticipation of the possibility (i) that the Corporation will not be a wholly-owned subsidiary of Pharmacia Corporation and that Pharmacia Corporation may be a majority or significant stockholder of the Corporation, (ii) that the officers and/or directors of the Corporation may also serve as officers and/or directors of Pharmacia Corporation, (iii) that the Corporation and Pharmacia Corporation may engage in the same or similar activities or lines of business and have an interest in the same classes or categories of corporate opportunities, and (iv) in recognition of the benefits to be derived by the Corporation through its continued contractual, corporate and business relations with Pharmacia Corporation (including possible service of officers and/or directors of Pharmacia Corporation as officers and directors of the Corporation), the provisions of this Article are set forth to regulate and shall, to the fullest extent permitted by law, define the conduct of the Corporation with respect to certain classes or categories of business opportunities that are presented to the Corporation as they may involve Pharmacia Corporation and its officers and directors, and the powers, rights, duties and liabilities of the Corporation and its officers, directors and stockholders in connection therewith.

2



Section 2.     Except as may be otherwise provided in a written agreement between the Corporation and Pharmacia Corporation, Pharmacia Corporation shall have no duty to refrain from engaging in a corporate opportunity in the same or similar activities or lines of business as the Corporation (and all corporations, partnerships, joint ventures, associations and other entities in which the Corporation beneficially owns directly or indirectly 50 percent or more of the outstanding voting stock, voting power, partnership interests or similar voting interests) engages in or proposes to engage in at the time of the initial public offering of the Corporation's Common Stock (and the Corporation hereby renounces any interest or expectancy, or in being offered any opportunity to participate in such business opportunities as may arise in which both the Corporation and Pharmacia Corporation may have an interest), and, to the fullest extent permitted by law, neither Pharmacia Corporation nor any officer or director thereof (except as provided in Section 3 of this Article V) shall be liable to the Corporation or its stockholders for breach of any fiduciary duty by reason of any such activities of Pharmacia Corporation. In the event that Pharmacia Corporation acquires knowledge of a potential transaction or matter which may be a corporate opportunity for both Pharmacia Corporation and the Corporation, Pharmacia Corporation shall, to the fullest extent permitted by law, have no duty to communicate or offer such corporate opportunity to the Corporation and shall, to the fullest extent permitted by law, not be liable to the Corporation or its stockholders for breach of any fiduciary duty as a stockholder of the Corporation by reason of the fact that Pharmacia Corporation pursues or acquires such corporate opportunity for itself, directs such corporate opportunity to another person, or does not communicate information regarding such corporate opportunity to the Corporation.
Section 3.     In the event that a director or officer of the Corporation who is also a director or officer of Pharmacia Corporation acquires knowledge of a potential transaction or matter which may be a corporate opportunity (as referenced above in Section 2) for both the Corporation and Pharmacia Corporation, such director or officer of the Corporation shall, to the fullest extent permitted by law, have fully satisfied and fulfilled the fiduciary duty of such director or officer to the Corporation and its stockholders with respect to such corporate opportunity, if such director or officer acts in a manner consistent with the following policy:
(a)
a corporate opportunity (as referenced above in Section 2) offered to any person who is an officer of the Corporation, and who is also a director but not an officer of Pharmacia Corporation, shall belong to the Corporation;
(b)
a corporate opportunity (as referenced above in Section 2) offered to any person who is a director but not an officer of the Corporation, and who is also a director or officer of Pharmacia Corporation shall belong to the Corporation if such opportunity is expressly offered to such person in his or her capacity as a director of the Corporation, and otherwise shall belong to Pharmacia Corporation; and
(c)
a corporate opportunity (as referenced above in Section 2) offered to any person who is an officer of both the Corporation and Pharmacia Corporation shall belong to the Corporation if such opportunity is expressly offered to such person in his or her capacity as an officer of the Corporation and otherwise shall belong to Pharmacia Corporation.


3



Section 4.     Any person purchasing or otherwise acquiring any interest in shares of the capital stock of the Corporation shall be deemed to have notice of and to have consented to the provisions of this Article V.
Section 5.     For purposes of this Article V only:
(a) A director of the Corporation who is Chairman of the Board or of a committee thereof shall not be deemed to be an officer of the Corporation by reason of holding such position (without regard to whether such position is deemed an office of the Corporation under the Amended and Restated By-Laws (the By-Laws) of the Corporation), unless such person is a full-time employee of the Corporation; and
(b) The term “Pharmacia Corporation” shall mean Pharmacia Corporation, a Delaware corporation (and any successor thereof) and all corporations, partnerships, joint ventures, associations and other entities (other than the Corporation (and all corporations, partnerships, joint ventures, associations and other entities in which the Corporation beneficially owns directly or indirectly 50 percent or more of the outstanding voting stock, voting power, partnership interests or similar voting interests)) in which Pharmacia Corporation beneficially owns (directly or indirectly) 50 percent or more of the outstanding voting stock, voting power, partnership interests or similar voting interests.
Section 6.     Anything in this Certificate of Incorporation to the contrary notwithstanding, the foregoing provisions of this Article V shall terminate, expire and have no further force and effect on the date that (i) Pharmacia Corporation ceases to beneficially own shares of common stock representing at least 20 percent of the total voting power of all classes of outstanding capital stock of the Corporation entitled to vote in the election of directors and (ii) no person who is a director or officer of the Corporation is also a director or officer of Pharmacia Corporation. Neither the alteration, amendment, termination, expiration or repeal of this Article V nor the adoption of any provision of this Certificate of Incorporation inconsistent with this Article V shall eliminate or reduce the effect of this Article V in respect of any matter occurring, or any cause of action, suit or claim that, but for this Article V, would accrue or arise, prior to such alteration, amendment, termination, expiration, repeal or adoption.
ARTICLE VI

Section 1. Subject to the rights of the holders of any outstanding series of Preferred Stock or any other series or class of stock as set forth in this Certificate of Incorporation to elect additional directors under specified circumstances, the number of directors of the Corporation shall be fixed, and may be increased or decreased from time to time, by resolution of the Board.

Section 2. Unless and except to the extent that the By‑Laws of the Corporation shall so require, the election of directors of the Corporation need not be by written ballot.


4



Section 3. The directors, other than those who may be elected by the holders of any outstanding series of Preferred Stock, shall, until the annual meeting of stockholders to be held in 2016, be classified with respect to the time for which they severally hold office into three classes, as nearly their equal in number as possible. The term of office for the class of directors elected at the annual meeting of stockholders held in 2011 shall expire at the annual meeting of stockholders to be held in 2014, the term of office for the class of directors elected at the annual meeting of stockholders held in 2012 shall expire at the annual meeting of the stockholders to be held in 2015, and the term of office for the class of directors elected at the annual meeting of stockholders held in 2013 shall expire at the annual meeting of stockholders to be held in 2016, with the members of each class to hold office until their successors are elected and qualified. Commencing at the annual meeting of stockholders to be held in 2014, directors succeeding those whose terms are then expired shall be elected to hold office for a term expiring at the annual meeting of stockholders held in the year following the year of their election and until their successors are elected and qualified. Commencing with the annual meeting of the stockholders of the Corporation to be held in 2016, the classification of the directors shall terminate and all directors shall be of one class and shall serve until the next annual meeting of stockholders or until their earlier death, resignation, removal or disqualification.

Section 4. Except as provided in the subsequent sentence and subject to the rights of the holders of any outstanding series of Preferred Stock or any other series or class of stock as set forth in or pursuant to this Certificate of Incorporation to elect additional directors under specified circumstances, any director or the entire Board may be removed from office at any time with or without cause, but only by the affirmative vote of the holders of at least 70 percent of the voting power of the outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class. Notwithstanding the immediately preceding sentence, until the annual meeting of the stockholders of the Corporation to be held in 2016, a director may be removed from office only for cause and only by the affirmative vote of the holders of at least 70 percent of the voting power of the outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, subject to the rights of the holders of any outstanding series of Preferred Stock or any other series or class of stock as set forth in or pursuant to this Certificate of Incorporation to elect additional directors under specified circumstances. Notwithstanding anything in this Certificate of Incorporation to the contrary and in addition to any other vote required by law, the affirmative vote of the holders of at least 70 percent of the voting power of the outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend, repeal or adopt any provision inconsistent with this Article VI.

Section 5. Subject to the rights, if any, of the holders of any outstanding series of Preferred Stock, newly created directorships resulting from any increase in the authorized

5



number of directors or any vacancies in the Board resulting from death, resignation, retirement, disqualification, removal from office or other cause shall be filled solely by the affirmative vote of a majority of the remaining directors then in office, even though less than a quorum of the Board. Any director so chosen shall hold office until his or her successor shall be elected and qualified and, if the Board at such time is classified, until the next election of the class for which such directors shall have been chosen. No decrease in the number of directors shall shorten the term of any incumbent director.

ARTICLE VII
In furtherance and not in limitation of the powers conferred by law, the Board is expressly authorized and empowered to adopt, amend, alter and repeal the By‑Laws of the Corporation at any regular or special meeting of the Board or by written consent, subject to the power of the stockholders of the Corporation to adopt, amend, alter or repeal any By‑Laws; provided, however, that with respect to the powers of the stockholders to adopt, amend, alter and repeal By‑Laws, notwithstanding any other provision of this Certificate of Incorporation or any provision of law which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any outstanding series of Preferred Stock required by law or by this Certificate of Incorporation (including any certificate filed with the Secretary of State of the State of Delaware establishing the terms of a series of Preferred Stock in accordance with Section 2 of Article IV), the affirmative vote of the holders of at least 70 percent of the voting power of the outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required for stockholders to adopt, amend or repeal any provision of the By‑Laws. Notwithstanding anything contained in this Certificate of Incorporation to the contrary and in addition to any other vote required by law, the affirmative vote of the holders of at least 70 percent of the voting power of the outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend, repeal or adopt any provision inconsistent with the preceding sentence.
ARTICLE VIII
The Corporation reserves the right at any time and from time to time to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, and any other provisions authorized by the laws of the State of Delaware at the time in force may be added or inserted, in the manner now or hereafter prescribed by law; and all rights, preferences and privileges of whatsoever nature conferred upon stockholders, directors or any other persons whomsoever by and pursuant to this Certificate of Incorporation in its present form or as hereafter amended are granted subject to the right reserved in this Article.
ARTICLE IX
A director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except to the extent such exemption from liability or limitation thereof is not permitted under the General Corporation Law of the State of Delaware as the same exists or may hereafter be amended.

6



Any amendment, repeal or modification of the foregoing paragraph shall not adversely affect any right or protection of a director of the Corporation existing hereunder with respect to any act or omission occurring prior to such amendment, repeal or modification.
ARTICLE X
Any action required or permitted to be taken at any annual or special meeting of stockholders of the Corporation may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding capital stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares of capital stock entitled to vote thereon were present and voted; provided, however, that after the first date on which Pharmacia Corporation and its affiliates cease to beneficially own the Pharmacia Required Percentage, any action required or permitted to be taken by stockholders may be effected only at a duly called annual or special meeting of stockholders and may not be effected by a written consent or consents by stockholders in lieu of such a meeting. Notwithstanding anything in this Certificate of Incorporation to the contrary and in addition to any other vote required by law, the affirmative vote of the holders of at least 70 percent of the voting power of the outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend, repeal or adopt any provision inconsistent with this Article X.
ARTICLE XI
The Corporation elects not to be governed by Section 203 of the General Corporation Law of the State of Delaware until the first date on which Pharmacia Corporation and its affiliates cease to beneficially own 15 percent or more of the total voting power of the outstanding shares of all classes of capital stock entitled to vote generally in the election of directors, at which time Section 203 of the General Corporation Law of the State of Delaware shall apply to the Corporation.

IN WITNESS WHEREOF, Monsanto Company has caused this Restated Certificate of Incorporation to be executed by David F. Snively, its Executive Vice President, Secretary and General Counsel, this 16th day of April, 2013.

/s/ David F. Snively    
Name: David F. Snively
Title: Executive Vice President, Secretary
and General Counsel


7

Dates Referenced Herein

This ‘10-Q’ Filing    Date    Other Filings
Filed on:6/27/13None on these Dates
For Period end:5/31/13
2/9/00
 List all Filings 
Top
Filing Submission 0001110783-13-000110   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 1, 3:54:58.1pm ET